Robertson Stephens Wealth Management LLC Has $355,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Robertson Stephens Wealth Management LLC reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 78.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,921 shares of the medical research company's stock after selling 7,062 shares during the period. Robertson Stephens Wealth Management LLC's holdings in Charles River Laboratories International were worth $355,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in Charles River Laboratories International by 46.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after buying an additional 1,679 shares during the period. E. Ohman J or Asset Management AB increased its position in Charles River Laboratories International by 225.0% in the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock worth $480,000 after buying an additional 1,800 shares during the period. Trust Point Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter worth $378,000. Boston Trust Walden Corp increased its position in Charles River Laboratories International by 4.3% in the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after buying an additional 8,338 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Charles River Laboratories International by 24.5% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,463 shares of the medical research company's stock worth $455,000 after purchasing an additional 485 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 0.6 %

Shares of CRL traded down $0.98 during midday trading on Wednesday, reaching $153.92. 1,278,385 shares of the stock were exchanged, compared to its average volume of 978,506. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The firm has a 50 day simple moving average of $178.90 and a 200-day simple moving average of $192.24. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The company has a market cap of $7.87 billion, a price-to-earnings ratio of 19.26, a P/E/G ratio of 6.47 and a beta of 1.37.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CRL. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. JPMorgan Chase & Co. decreased their price target on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a research note on Monday, February 3rd. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Finally, The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).